r3H]Cyclofoxy (CF: 17-cyclopropylmethyl-3, 14-dihydroxy-4,5-a-epoxy-6-�-f1uoromorphinan) is an opioid antagonist with affinity to both mu and kappa sub types that was synthesized for quantitative evaluation of opioid receptor binding in vivo. Two sets of experiments in rats were analyzed. The first involved determining the metabolite-corrected blood concentration and tissue dis 183 potential (BP) varied over a much broader range (BP = 0.6-32). In vivo estimates of the opioid receptor dissoci ation constant were similar for different brain structures (Ko = 2.1-5.2 nM), whereas the apparent receptor den sity ( B maxl varied between I (cerebellum) and 78 (thala mus) pmol/g of brain. The receptor dissociation rate con stants in cerebrum (k4 = 0.08-0.16 min -1; koff = 0.16-0.23 min -I ) and brain vascular permeability (PS = 1.3-3.4 ml/min/g) are sufficiently high to achieve equilibrium conditions within a reasonable period of time. Graphical analysis (Patlak and Blasberg, 1985) of the data is inap propriate due to the high tissue-loss rate constant (kb = 0.03-0.07 min -I ) for CF in brain. From these findings, CF should be a very useful opioid receptor ligand for the estimation of the receptor binding parameters in human subjects using rI8F]CF and positron emission tomogra phy.
tribution of CF in brain I to 60 min after i. v. bolus injec tion. The second involved measuring brain washout for 15 to 120 s following intracarotid artery injection of CF. A physiologically based model (Sawada et aI., 1990a ) and a classical compartmental pharmacokinetic model (Wong et aI., 1986a) were compared. The models included dif ferent assumptions for transport across the blood-brain barrier (BBB); estimates of nonspecific tissue binding and specific binding to a single opiate receptor site were found to be essentially the same with both models. The nonspe cific binding equilibrium constant varied modestly in dif ferent brain structures (Kcq = 3-9), whereas the binding A great deal is currently known about the distri bution of opioid receptors in mammalian brain (At weh and Kuhar, 1977a.b) . In vitro studies of dis sected, homogenized brain regions (Hiller et aI ., 1973 ; Kuhar et aI., 1973 ; Pert and Snyder, 1973) as well as autoradiographic patterns of opioid receptor distribution on thin sections of rat brain (Young and Kuhar, 1979; Herkenham and Pert , 1982) consis tently show high levels of radiolabeled opioid binding sites in specific brain regions that include the caudate nucleus, thalamus, and amygdala. A similar pattern of anatomical localization has been demonstrated fo llowing i.v. administration of ra diolabeled opioids by tissue dissection (Pert et aI ., 1975a) and autoradiographic (Pert et aI ., 1975b) techniques. There is very little or undetectable opi oid binding in cerebellum of the rat , whereas opiate receptor subtypes are present in human cerebellum (Gibo et aI., 1990) .
A number of opiate agonists and antagonists have been labeled with IIC (Frost et aI ., 1985 ; Jones et aI., 1988) for imaging opiate receptors using posi tron emission tomography (PET) . Other effo rts have been directed toward the synthesis of specific ISF-Iabeled ligands (Pert et aI ., 1984 ; Chesis and Welch, 1988) because of the temporal and opera tional advantages with a longer-decaying radionu clide. A derivative of (-)-naltrexone (6-deoxy-613-fluoronaltrexone; (-)-cyclofo xy) was synthe sized that can be labeled with either ISF or 3H, and was developed to provide a new ISF-Iabeled ligand for human PET studies (Burke et aI ., 1985) . Cyclo fo xy (CF) demonstrates high affinity for both mu and kappa opioid receptor subtypes based on in vitro experiments (Rothman et aI ., 1987 ; Rothman and McLean, 1988) . Pharmacological studies under the auspices of the Committee on Problems of Drug Dependence (Aceto et aI., 1987) have shown that CF (NIH 10,357) is a full narcotic antagonist in vivo (two and ten times more potent than naltrexone and naloxone, respectively) with no measureable ago nist properties in both rodents and primates. The first demonstration that CF might prove useful for labeling opioid receptors in vivo came from a study using PET (Pert et aI., 1984) and quantitative auto radiography (Ostrowski et aI., 1987) . Injection of the acetylated analog, eSF]acetyl-CF, was the first PET study to demonstrate opioid receptor-dense brain regions in a living baboon (Pert et aI., 1984) ; this localization of label was stereospecifically dis placed by intravenous injections of the active enan tiomer of the opioid antagonist (-)-naloxone, but not the inactive enantiomer ( + )-naloxone.
In this study, we measured the in vivo distribu tion of eH]CF in various regions of the rat brain J Cereb Blood Flow Metab. Vol. 11. No. 2, 1991 after i. v. bolus injection and after intracarotid ar tery injection, and the data were analyzed by dif ferent pharmacokinetic models. The issues raised in this report focus on three points: (a) a comparison of different methods of data analysis based on a physiological model (Sawada et aI., 1989 (Sawada et aI., , 1990a , a classical compartmental model (Wong et aI ., 1986a; Logan et aI ., 1987) , and a graphical method (Patlak and Blasberg , 1985) ; (b) a quantitative comparison between in vivo and in vitro estimates of specific receptor-CF binding parameters; and (c) potential clinical applications for CF imaging and quantita tion of opioid receptor binding potential, affinity, and number in human brain using eSF]CF and PET.
MATERIALS AND METHODS
Chemicals and synthesis [15 ,16(n ) -'HjCyclofoxy [a fluorinated analog of (-)-naltrexone; 6-deoxy-6[3-fluoronaltrexone; 20.5 Cil mmol, 59.4 mCi/mg) was prepared by Amersham Corpo ration (Arlington Heights, IL, U.S.A.) by catalytic reduc tion of (-)-15,16-didehydrocyclofoxy using tritium gas. The synthesis, purification, and tritiation of CF have been described in greater detail elsewhere (Ostrowski et al., 1987) . 46SC microspheres (15 fLm in diameter, 5 mCi/g, in 10% dextran and 0.01 vlv Tween 80) and [14C]iodo antipyrine (lAP) (N-methyl-14C; 40-60 mCilmmol) were supplied by Dupont NEN Products (Boston, MA, U.S.A.). All other chemicals were obtained from com mercial sources and were of analytical grade.
Purity of isotopically labeled compounds
The isotopic purity of [,H]CF was >98% as determined by high pressure liquid chromatography (HPLC) (Model 3B, Perkin-Elmar, Norwalk, CT, U.S.A.) using a 25 cm Ultrasphere Column (ODS 5fL; Beckman Instruments, San Ramon, CA, U.S.A.), a solvent system composed of buffer:acetonitrile (65:35, v:v; the buffer was 10 mM po tassium monophosphate and 1 mM dodecyl phosphate at pH 2.1) and a flow rate of 1.0 mllmin. The isotopic purity of r14C]IAP was >98% as determined by silica gel thin layer chromatography using two solvent systems: chi oro form:methanol (95:5, v:v) and benzene:ethyl acetate (7:3, v:v).
Assay 'H and 14C radioactivity was determined using a stan dard double-label technique with external standard quench correction in a Packard 4000 beta liquid scintilla tion spectrometer (Packard Instrument Company, Dow ners Grove, IL, U.S.A.). 3H radioactivity from the HPLC column was measured and recorded by a Flow 1 Beta system (Radiomatic Instruments, Camberra, Tampa, FL, U.S.A.). The activity of 46SC microspheres was deter mined in a three-channel Packard 5385 gamma spectrom eter.
Animal experiments
Male Sprague-Dawley rats, weighing 250 to 280 g, were obtained from Taconic Farms (Germantown, NY, U.S.A.). Two sets of experiments were performed: (a) brain uptake and washout over 60 min after bolus i.v. injection and (b) brain uptake and washout over 2 min after intracarotid artery injection.
For the i.v. experiments, animals were injected with either 10 fLCi (0.5 nmol), 68 fLCi (3.3 nmol), or 153 fLCi (7.5 nmol) of [3H]cyclofoxy via a femoral vein catheter. An additional high dose (500 fLCi; 24.4 nmol) was also examined similarly in autoradiography and metabolism studies (see below). Femoral vessel catheterization (PE50 polyethylene tubing; one vein and two arteries) was per formed under gas anesthesia (halothane/nitrous oxide/ oxygen: 1.5/30170, v/v/v). The experimental animals were partially restrained in plaster casts and allowed to recover from anesthesia for at least I h; physiological parameters were monitored and body temperature was maintained at 36-3rC with heat lamps. Arterial blood gases [p0 2 ' pC0 2 , and pH: 97.8 ± 14.0 (SD) torr, 37.6 ± 3.5 torr, and 7.39 ± 0.03, respectively, n = 40] and mean arterial blood pressure (119 ± 16 mm Hg) were measured just prior to the experiments. Arterial blood (50-100 fLl) was sampled during the experiments (at 0.25, 0.5, 0.75, 1, 1.5, 2.0, 3, 4, 5, 10,20, 30,45, and 60 min) ; blood and plasma radioac tivity was measured. The animals were decapitated at the end of the experiment [I, 2, 5, 10, 15,30,45 , and 60 min for the lowest dose (0.5 nmollrat) and at 10, 30, and 60 min for the other doses]. Various brain regions were dis sected and radioactivity of the tissue samples was mea sured. The mean hematocrits at the end of these experi ments ranged from 38.8 to 41.4% and were not correlated with experiment duration.
For the i.a. experiments, rats were anesthetized with pentobarbital (45 mg/kg i.p.) and a polyethylene catheter (PE260) was inserted in the trachea to maintain stable breathing. The vessels of the right side of the neck were exposed. A 50 fLI bolus of whole blood containing 2 fLCi (0.1 nmol, 2.0 nM) of eH]cyclofoxy and 0.5 fLCi of [14C]lAP or 46SC microspheres (approximately 100, 000 spheres) was rapidly injected via a 29-gauge needle into the carotid artery (Oldendorf, 1970) . Physiological param eters were monitored and body temperature was main tained at 35-37°C with heat lamps. Arterial blood gases [p02' pC0 2 , and pH: 103 ± 20 (SD) torr, 43 ± 4 torr, and 7.42 ± 0.05, respectively, n = 19) and carotid artery blood pressure (144 ± 20 mm Hg systolic and 100 ± 15 mm Hg diastolic, n = 18-20) were measured just prior to the experiments. Animals were decapitated at 0.25, 0.5, I, 1.5, and 2 min after injection, various brain regions were sampled, and tissue radioactivity was measured.
Autoradiography and cyclofoxy metabolism
[3H]Cyclofoxy (500 fLCi, 24.4 nmol) was injected intra venously in conscious rats. Serial blood samples were obtained as described above and the animals were decap itated at 10, 30, and 60 min. Frontal cortex and a portion of the cerebellum were sampled for radioactivity mea surement from the left half of the brain (see above) and the rest of the left hemisphere was used for measuring CF metabolites in brain. The right half was used for autora diographic analysis. Sections of brain tissue were pre pared for autoradiography as previously described (Blas berg et aI., 1981) . Serial sections were cut 20 fLm thick at intervals of 600 fLm. The tissue sections were placed in a cassette along with 3H standard (Amersham) and ul trafilm (Amersham) for a 12-week exposure period at room temperature.
Brain tissue for metabolite analysis (cortex and cere bellum) and plasma samples obtained at various times after injection of CF were processed for HPLC. Brain tissue (50-100 mg) was added to 1 ml of methyl alcohol and sonicated (10 s x 2) using a W-375 cell disruptor fitted with a microtip. The sample was vortexed, centrifuged, and the supernatant was stored in ice. The precipitate was washed three times with 0.5 ml of methyl alcohol and combined with the supernatant, which recovered >95% of total radioactivity in the original homogenate. A 3 cc analytical C-18 column (Analytichem International, Har bor City, CA, U.S.A.) was conditioned with 5 ml of meth anol followed by 5 cc of distilled water; 10 fLl of ammo nium hydroxide was applied to the column just prior to use. The supernatant was diluted 1: 10 with distilled water and applied directly to the column, and the column was washed with 3 ml of distilled water. Parent eH]CF and radiolabeled metabolites retained by the column were eluted with 3 ml of methanol, evaporated to dryness un der N 2 gas, and resuspended in 150 fLl of HPLC buffer. Fifty to 80 fLl of the resuspension was assayed by HPLC. For plasma samples, I ml of borate buffer (0.2 M, pH 9.0) and 0.2 ml of octanesulfonic acid (0.1 M, pH 4.9) were added to I ml of plasma. The sample was vortexed and applied to a preconditioned C-18 column (without ammo nium hydroxide) and processed through HPLC as de scribed above. Recovery of CF from the C-18 column was determined by spiking r3H)CF into a blank plasma or tis sue homogenate sample, and processing the samples as described above; essentially all radioactivity (>98%) was eluted in the methanol fraction. The unchanged or parent fraction of CF in each sample was calculated by the re covery from the C-18 column treatment and subsequent HPLC analysis.
The unchanged fraction in plasma radioactivity was also determined by liquid phase partitioning using an ethyl acetate-borate buffer (pH 9.0) extraction method as previously described (Kawai et a!., 1990a) . The ethyl ac etate extraction ratio of plasma radioactivity (EER) was calculated by where As, Vs' and Vo are the measured radioactivity of the sample, the sample volume, and the original volume of the ethyl acetate (subscript I) and aqueous (SUbscript 2) phases, respectively.
The fraction of radioactivity in plasma representing un changed CF (F oJ was obtained by
where EERo is the value obtained for the injectate. EERa varied between 0.911 and 0.926 (0.917 ± 0.006, mean ± SD); recovery of total radioactivity in the ethyl acetate and aqueous phases was 99.9 ± 3.6%.
Binding of [3H]CF to plasma protein and whole blood
All of the procedures were carried out immediately af ter blood collection from the donor rat. Plasma protein binding was determined by adding 0.5 fLCi of [3H]CF to 0.5 ml of plasma, incubating for 10 min at 37°C, and ul trafiltration (Centricon; Amicon, Danver, MA, U.S.A.) as previously described (Sawada et aI., 1990a,b) . The free (unbound) fraction in plasma (fp) was calculated from
where Cp and Cu are the measured concentration in plasma and ultrafiltrate, respectively. The adsorption of CF in saline solution to the ultrafiltration membrane was negligible.
For determining the binding of CF to red cells, blood (1 ml) was incubated with 1 fLCi of eH]CF at 37°C for 10 min. Hemolysis was negligible during incubation and the hematocrit was unchanged and similar to the values mea sured in vivo. Blood to plasma (Rb) and red blood cell to plasma (Rre) concentration ratios of parent CF and the free (unbound) fraction in blood (f�) were subsequently calculated under the assumptions of equal concentrations of unbound CF in red cell and plasma water and rapid (instantaneous) equilibration across red cell membranes:
where Cb, Cre' Hc, and Wb are the concentration of CF in arterial blood and red cells, the hematocrit, and the water content of blood (wb = 0.82 ml/g of rat blood) (Altman, 1961) , respectively.
Calculations of CF blood concentration
The parent fraction, F C F' in each plasma sample was determined by ethyl acetate extraction [Eq .
(2)] or HPLC methods and Cp was calculated from the measured (total) plasma radioactivity (C;) by (7) The value of metabolite-corrected concentrations of eH]CF in each arterial blood sample (Cb; percent dose/g of blood) was calculated by assuming that Rb is constant throughout the in vivo experiments and identical to that measured in vitro:
Calculated Cb values for each of the four administered doses were fitted to a four-exponential equation using nonlinear least-squares regression. The best-fitted equa tion was used to describe the input function [Cb(t)] in the kinetic analysis.
Correction for intravascular radioactivity
The measured whole blood to plasma concentration ra tio (q/C;), including both CF and its metabolites, ranged from 0.8 to 1. measured radioactivity in brain tissue (percent dose/g of tissue; Am) was corrected for intravascular radioactivity (AT) by where C:e is the concentration of total radioactivity in red cells and was calculated by
Vp is the plasma volume (5-15 fLl/g of tissue in various structures) and Vre is the red cell volume (3-9 fLl/g of tissue) in brain tissue (Blasberg et aI., 1983) .
Model development
Two different pharmacokinetic models ( Fig. IA and B ) were used to analyze the 1-60 min data following i. v. injection of the lowest CF dose (0.5 nmol/rat), assuming linearity (concentration independence) for all kinetic pa rameters. These models differ from each other in the as sessment of blood-brain barrier (BBB) transport. Model A includes the permeability surface area product (PS \ ) of brain capillaries, the tissue efflux rate constant (k2), and the knowledge of regional blood flow (F), while model B defines the brain tissue influx clearance (K?) and efflux rate constant (k�). Two independent tissue binding sites were assumed for both models; one site represents rapid nonspecific binding expressed by an equilibrium constant (Keq and �q) and the other site represents specific re ceptor binding expressed by association and dissociation rate terms (k3, k4 and kf, k� for models A and B, respec tively). In addition, we assumed a fixed relationship for BBB transport in both models:
where Aw is the tissue to blood water partition coefficient (Blasberg et al., 1988 ; for rat brain, Aw = wT/Wb = 0.96 ml of blood/g of brain, where WT is the water content of brain [wT = 0.79 ml of water/g of rat brain (Grome et aI., 1988) ].
Physiologically based pharmacokinetic model
In this analysis (Model A, Fig. I ), the tissue compart ment is assumed to be homogenous (well mixed) with respect to the spatial distribution (concentration) of the test substance (Sawada et aI., 1989) , and is similar to that CB Compartment 1 represents the intravascular pool; compartment 2 represents the pool of "free," unbound drug; compartment 3 represents the pool of bound drug where one subcompartment represents rapid (instantaneous) nonspecific binding (An) and the other subcompartment represents slower receptor-specific, saturable binding (Ar) with measurable rate parameters. PS1, k2' K�, and k� are transport pa-AT rameters. Keq, K�q, k 3 ' k�, k4' k�, k�n' kott, and 8max are binding parameters.
described by Johnson and Wilson (1966) . Within the cap i1lary, however, the concentration of the test substance is a function of both distance along the capillary and time. The physiologically based model for [3H1CF distribution in all brain regions is shown in Fig. IA and the differential equation and solution for the analysis are shown in Ap pendix II. Regional blood flow values were obtained from Kawai et al. (1990a) . Four unknowns (PSt' Ke q , k 3 , k 4 ) were determined by a nonlinear least-squares method (NLS) (Hanano, 1989 ) and a numerical inverse Laplace transform (Hosono, 1983) . The trapezoidal method was used for integration of Eq. (AI8) in Appendix II. The corrected mean tissue concentration at the time of decap itation and the blood concentration time profile after ad ministration of CF for each experimental time period was used in the analysis.
Classical pharmacokinetic model
Pharmacokinetic modeling based on model B (Fig. I) is similar to that previously described (Wong et aI., 1986a; Logan et aI., 1987) , except for the fixed relationship be tween K� and k� defined by Eq. (II). In this compartmen tal analysis, the effects of blood flow are included in the estimated parameters (namely, K� and k�). The differen tial equations and solution for the analysis are shown in Appendix II. Four unknown parameters (K�, K� q , k�, and k�) were determined by the same data-fitting methods de scribed above for the physiological model. Model B was also used to simulate brain washout profiles of [3H1CF. The procedure for the analysis is also shown in Appen dix II.
Nonlinear pharmacokinetic model
Model B (Fig. I ) was used to analyze the i. v. injection experiments (0.5-24.4 nmol/rat) to estimate kon. kotl', and Bmax (see Appendix I and Ill); the estimates were deter mined by a NLS method: SALS and Runge Kutta Merson (Yamaoka and Nakagawa, 1983) . The differential equa tion and solution for the analysis are shown in Appendix II. In this analysis, we assume that K� and K� q and the relationship shown in Eq. (I 1) (K�/k� = fb . Aw) are un affected by CF concentration (dose) and used the esti mates obtained with i. v. injection of the lowest dose (0.5 nmol/rat).
Statistical analysis
All means are presented with their standard deviation (mean ± SD). The residual sum of squares (SS) is defined for the NLS fitting (Hanano, 1989) or the SALS fitting (Yamaoka and Nakagawa, 1983 ) by the following equa tion:
where Cij is the value of the jth point on the ith experi mental time course, . t;(t j ,k) is the theoretical equation to fit that is derived from the model used in this study, l j is time at the jth point, k is the transport parameter to be esti mated, and Wi j is the weight of data points. In this study, Cij is equivalent to (AT)u and [W ij = (I/Cij) 2 1 was used as the weighting function since there was a fairly uniform coefficient of variation in tissue concentration over time and counting statistics were not an issue. In order to check for trends between observed and calculated values, we compared the normalized residual (NR) profiles:
We used the Akaike information criterion (AIC) to evaluate different models (Akaike, 1976; Tanabe, 1976) :
where N is the number of experimental data points and P is the number of parameters in an estimated model.
RESULTS

Metabolism of [3H]CF
The fraction of radioactivity representing parent CF in brain tissue obtained from the left cortex and cerebellum and in plasma samples at various times after i.v. injection was determined. As shown in Fig. 2B , HPLC of the 60-min plasma sample con tained three main peaks. Two peaks appeared at 5 to 8 min; the retention times are consistent with hydrophilic metabolites of CF since they are seen in the aqueous phase ( Fig. 2D ) but not the ethyl ace tate phase of the plasma extract (Fig. 2C ). The third peak in plasma appeared at 24 min ( Fig. 2B ) and it corresponded to the only peak in the ethyl acetate extract (Fig. 2C ); this retention time is the same as stock l3H]CF ( Fig. 2A ). In the case of cortex and cerebellum, a single HPLC peak at 24 min was ob- served for all experimental times and corresponds to eHlCF ( Fig. 2E and 2F , respectively). The un changed or parent fraction of tissue radioactivity was calculated from this HPLC study and ranged from 0.97 to 1.0. The correspondence between HPLC and ethyl acetate methods to measure the parent fraction of plasma eHlCF at various times after injection is shown in Fig. 3 . There was a close correlation be tween the ethyl acetate extraction and HPLC determined values of the parent CF fraction in plasma between 1 and 60 min ( Fig. 3 , insert) . The plasma parent fraction vs. time profiles for the four different doses of CF (0.5-24.4 nmol/rat) were mea sured by the ethyl acetate extraction method. All time courses were similar to that shown in Fig. 3 and no dose dependency was observed .
In vivo autoradiography
Autoradiographic images of eHlCF distribution in brain after intravenous bolus administration are shown in Fig. 4 . The earliest image (10 min after injection) shows a heterogenous distribution of 3 H that appears to be similar to that of a blood flow marker (e.g., [14C]IAP) (Sakurada et aI ., 1978) . The autoradiograms obtained at 30 and 60 min after in jection show a different heterogeneous distribution of 3 H from that at 10 min with greater washout of radioactivity from some structures compared to others. High activity is seen in clusters throughout the caudate nucleus, along its lateral surface just below the corpus callosum, and in the nucleus ac- Vol, 11, No, 2, 1991 cumbens (column A); high activity is also noted in the amygdala, medial and dorsal nuclei of the thal amus, entorhinal cortex, choroid plexus, and to a lesser extent in the CA3 region of the hippocampus (columns B and C); very high activity is seen in the interpeduncular nuclei, with lesser activity in the lateral portion of the substantia nigra and the pre and parasubiculum (column D). The image contrast of radioactivity localization in these structures is enhanced by 30 and 60 min (rows 2 and 3, respec tively). Modest levels of radioactivity are seen in other structures such as cortex and hippocampus, whereas in white matter tracts the levels of radio activity are low. In cerebellum (column E), a pro gressive washout of radioactivity is seen in both gray and white matter. This pattern of eHlCF dis tribution in vivo is similar to that observed with r 3 H]diprenorphine (Atweh and Kuhar, 1977a,b) .
Intravenous injection: blood and tissue concentration profiles
The concentration-time profiles of parent CF in blood and tissue (Figs. 5 and 6) were obtained from the metabolism (Fig. 3 ) and blood binding data; ip' Rb, and Rr c lEgs . (3)-(5)] were 0.76 ± 0.04, 1.30 ± 0.08, and 1.75 ± 0.02 (n = 4), respectively;jb [Eg. (6)] was calculated from mean values of ip and Rb and was 0.48. The corrected blood concentrations were calculated by Eg. (8) and shown in Figs. 5A and 6A. These blood curves were fitted to a sum of exponentials; the coefficients and exponents of the fits are given in the legend to Fig. 6 
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dose/g of brain) and apparent distribution volumes (ml/g of brain) in thalamus, frontal cortex, and cer ebellum fo llowing the lowest dose of CF (0. 5 nmol! rat) are presented in Fig. 5 . The concentration of eH]CF in cerebellum was consistently lower than that in cerebrum (thalamus and cortex); washout of eH]CF from cerebellum was rapid and parallel to .... that in blood after 15 min ( Fig. SA) . A similar initial uptake but slower washout of eH]CF were ob served in thalamus compared to that in frontal cor tex. A "secular" or "transient" equilibrium of the tissue to blood concentration ratio (steady state of the apparent tissue distribution volume, ml/g) for eH]CF was observed in cerebellum at 15 min and in cortex at 30-45 min, but not in thalamus during the 60-min experimental period ( Fig. 5B ). There was a slight overshoot phenomenon in cerebellum 5 min after intravenous bolus injection ( Fig. 5B ), due to the initial rapid decline in [ 3 H]CF blood levels ( Fig.  SA) .
At the higher dose levels (3.3, 7.5, and 24.4 nmol/ rat), tissue uptake (% dose/g) of CF in thalamus and frontal cortex was smaller than that for the lowest dose (0.5 nmol/rat) at 30 and 60 min (Fig. 6) . In contrast, there were no differences in CF levels (% dose/g) in cerebellum and blood when comparing the four different dose experiments.
Intra-arterial injection: brain washout profiles
The washout profiles of eH]CF, lI4C]IAP, and 46SC microspheres from brain 15-120 s after intra carotid artery injection are shown in Fig. 7 . Micro spheres were trapped in the brain and remained at a constant level during the 2-min experimental pe- 1991 riod . At IS s after injection, the apparent extraction ratio of CF is equal to or slightly smaller than that of [14C]IAP; the subsequent washout of [ 3 H]CF from brain was slower than that of [14C]IAP.
Linear (tracer) pharmacokinetics
Physiological pharmacokinetics (model A; Fig.   1 ). Tissue distribution data of CH]CF (0.5 nmol/rat) in frontal cortex, parietal cortex, occipital cortex, thalamus, caudate putamen, hippocampus, me dulla, and cerebellum were fitted to Eqs. (AI6) and (A 18) in Appendix II. Values of blood flow for each structure were obtained from similarly performed experiments in conscious rats (Kawai et aI., 1990a) . A composite of all values is shown in Table 1 . The estimated PSI values are larger than regional blood flow. The nonspecific binding equilibrium constant Keq varied somewhat in different brain structures, ranging between 3 and 9. The receptor dissociation rate constant k4 in cerebrum showed less variation between regions ranging from 0.07 to 0.15 min -1. The receptor association rate constant k3 and the receptor binding potential kik4 in cerebrum showed regional differences, ranging from 1.1 to 2.4 min-1 and 9-32, respectively. In cerebellum, large errors were associated with the estimates of k3 and k4 com pared with cerebrum. The receptor binding poten- Caudate Putamen
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- tials k31k4 in cerebrum were two-to sixfold greater than the nonspecific binding equilibrium constant K e q · Classical pharmacokinetics (Model B; Fig. 1 ).
Using the same tissue and blood time-activity data, parameter estimates were obtained by fitting the data to Eqs. (A28) and (A29) in Appendix II and are shown in Table 2 . Qualitatively, we obtained very similar results to that described above for the phys iological pharmacokinetic model. Normalized resid ual plots [Eq. (13) ] were constructed for all fits ob tained with the two models. The residuals were fo und to be randomly distributed and no difference was observed between the models. There are essen tially no differences in the values of K�q (Keq), V-} (VT), k� (k3), k�/k� (k3Ik4), and E{ (E I ) between clas sical and physiological pharmacokinetic models.
Nonlinear (receptor saturation) pharmacokinetics
The time course of CF concentration (pmol/g) in frontal cortex, cerebellum, and thalamus for differ ent injected doses of CF (0.5, 3.3, 7.5, and 24.4 nmol/rat) are shown in Fig. 8 . The fitted solid line is based on the solution of Eqs. (A35) and (A36) in Appendix II and the estimated values of k�n' ko[[' KD, and Bm ax; this least-squares fit assumes a single receptor site and bimolecular reaction kinetics. The range of values for structures in the cerebrum are 0.04-0.06 nM -I min -I for kon' 0. 16-0.23 min -I for kof[' 2.1-5.6 nM for KD, and 28-79 pmol/g of brain for Bm a x (Table 3 ). In cerebellum, kon and koff values are high and associated with large error estimates. The values of Bm a x and the binding potential in cer ebellum are very low (and are not significantly dif ferent from zero) compared to various structures in the cerebrum.
DISCUSSION
The ability to image neuroreceptors with radiola beled ligands and PET or single-photon emission tomography in animal and human brain raises the possibility that receptor density and receptor affin ity can be measured using the appropriate experi mental protocol and mathematical model to analyze the data (Wagner et aI ., 1983 ; Frost and Wagner, 1984; Mintun et aI., 1984; Wong et aI., 1984; Farde et aI., 1985; Frey et aI ., 1985; Samson et aI., 1985 ; Wong et aI ., 1986a,h; Perlmutter et aI., 1986; Logan et aI. , 1987; Pappata et aI., 1988; Frost et aI., 1989; Sawada et aI., 1990b) . Mintun et al. (1984) and Perl mutter et al . (1986) have proposed an explicit model for the in vivo analysis of eSF]spiroperidol binding in brain. Their compartment model included a cap illary compartment and the transport parameters (PS and blood flow) were independently evaluated. They assumed that distribution of the ligand was uniform in both capillary and brain tissue compart ments, namely each compartment was well mixed. This is the so-called venous equilibrium model. Wong et al . (I986a) have proposed a classical com partment model for ligands, such as N-methyl spiperone, with low extraction across the BBB. Frost et al . (1989) and Sawada et al . (1990b) have adopted similar compartmental models to analyze their e IC]carfentanil and 3-Quinuclidinyl 4-e25I]io dobenzilate nI25I]IQNB) data, respectively. The model proposed by Johnson and Wilson (1966) and expanded by Sawada et al. (1989) may be more suit able for analyzing the behavior of ligands that cross the BBB more rapidly from the point of view of the topographical characteristics of the microvascula ture in brain (Pawlik et aI., 1981 ; Yoshida and Ikuta, b Regional blood flow (F) was determined using [1 4 C]iodoantipyrine in a similar sct of animals (Kawai et aI., 1990a ) and used to estimate PS I ' Keq, k3, and k 4 . 'Two-compartment model; A, = 0, k3 = k4 = 0 ( Fig. I) .
j Estimated values ± SEM of the estimates.
1984)
. In this physiological model, the tissue com partment is always homogenous (well mixed) , whereas the concentration of the ligand within the capillary is a function of both distance along the capillary and time. The difference in the transport parameter estimates between the venous equilib rium model and the Johnson-Wilson model is min imized when the ligand or test compound permeates the BBB very rapidly (Sawada et aI ., 1989) .
Comparison between physiological and classical pharmacokinetic models
The classical pharmacokinetic model proposed by Wong et al. (1986a) for analyzing time-activity data of ligands with low BBB permeability is said not to require knowledge of blood flow. They argue that the transport constants for influx and efflux determine the net flux of tracer across the BBB for all times between injection to the establishment of a steady state. For this class of ligand, K� is nearly equal to PS I and the physiological and the compart ment models will be essentially identical. In the case of ligands that permeate brain capillaries rap idly , PS I > K l' some differences in the efflux rate constant (k2, k�), receptor-ligand association (k3, k�), and dissociation (k4, k�) rate terms may be ex pected between the physiological and classical pharmacokinetic models. The values of PS I and k2 in the physiological model were 1.9 to 2 . 5 times greater than the values of K� and k� in the classical model for CF (Tables 1 and 2 ). However, little or no difference was observed in the association (k3, k�) and dissociation (k4, k�) rate constants and the bind ing potentials (k31k4 and k�/k�; K eq , and K� q ) and the total volume of distribution (VT, Vj-.) between the two models (Tables 1 and 2). The agreement of these parameters suggests that the differences in BBB transport described by these two models have little effect on and results in essentially the same concentration-time profile of "free," unbound ligand in brain tissue. Thus, the classical model is applicable for the estimation of CF-receptor binding parameters.
All of the linear parameter estimations were an al yzed using data from the lowest administered dose of eH]CF (0.5 nmol/rat). This dose was sub sequently found to be in the linear range based on both the nonlinear analysis (Table 3 ) and the brain washout study (Fig. 7) . The blood concentration af ter i.v. injection of 0.5 nmol/rat was less than 0. 5 nM, except during the first few minutes (Fig. 5) ; the free, unbound concentration in blood if b . Cb < 0. 24 nM) was less than one-tenth of the Kn estimates (Table 3) . We also performed a simulation of the i.a. injection, brain washout experiments. The adminis tered i.a. dose (0. 1 nmol/rat) corresponds to an i. v. dose in the capillaries that is >0. 5 nmol/rat. Com paring the linear model [Eqs. (A22) and (A23)] and the nonlinear model (Eqs. (A35) and (A36) with nonlinear parameters from Table 3 ] in Fig. 7 shows a close correlation between both the linear (solid line) and nonlinear (broken line) simulations to each other and to the observed tissue values. This result suggests that the effect of partial receptor saturation was negligible in the i.a. experiments and in the first few minutes after i. v. injection of the lowest dose of CF (0.5 nmol/rat).
Comparison between compartmental analysis and graphical analysis
Graphical analysis ( Fig. 9) (Patlak and Blasberg, 1985) was applied to the CF data obtained at the lowest dose (0.5 nmol/rat) as described previously (Sawada et aI., 1990b) . The curvature of the graph ical plot reflects a fairly rapid loss of CF from the tissue (see inset in Fig. 9A ). Presumably, this loss is due to dissociation of CF from the opioid receptor and efflux across the BBB. The steady-state uptake rate K and K+ (slope of the linear portion of the graphical plot) and the tissue loss constant kb and k{, for CF in various brain regions can be determined reliably providing that kb and k{, are small in relation to other eigenvalues of the system (Patlak and Blas berg, 1985) . Despite the linear plots in Fig. 9 , the conditions for appropriate graphical analysis are not likely to be met by CF. The slopes and kb (k�) values were compared to corresponding values calculated from the rate constants determined by conventional compartmental analysis (Table 4 ). The observed differences reflect the uncertainty of the assump tion that kb was smaller than the other eigenvalues of the system. The k�/ K� and kb/�4 ratios are sub stantial and range from 0.15 to 0.73 and 1 . 5 to 7.2, respectively (where �4 is the fourth exponential de scribing the blood clearance of CF; see the legend to Fig. 5, 0 .5 nmol/rat). In the case of IQNB, a ligand with very high binding affinity to muscarinic receptors (Sawada et aI., 1990b) , the values of K and kb calculated by compartmental analysis were much closer to those estimated by graphical analy sis; this would be expected since the k4/k2 and kb/�4 ratios were substantially lower with IQNB , ranging from 0.001 to 0.003 and 0.20 to 0. 73, respectively. a KD = kor/kon. b Binding potential: BP = B ma )(K D . Vd), where Vd is the physical volume of distribution equivalent to WT' the water content of brain (0.79 mllg of brain).
Comparison between in vivo and in vitro estimates of Ko and Bmax
Rothman and McLean (1988) reported in vitro K D (0.5 nM for mu sites and 0.72 nM for kappa sites) and Bmax (78 fmol/mg of protein for mu sites and 151 fmol/mg of protein for kappa sites) values. Because of the similarity of KD values for the mu and kappa sites obtained in vitro and our limited amount of experimental data, we assumed a single receptor model with one set of KD and Bmax values for our in vivo analysis. The in vivo KD values estimated here (2. 1-5.6 nM) are greater than the in vitro KD value (Table 5) . A similar in vitro-in vivo relationship has been reported for the opioid receptor antagonist, eH]diprenorphine (Perry et aI., 1980; Sadee et aI ., 1982) . The differences in the KD values could be due to several factors including the experimental condi tions (e.g., temperature , buffer, and) of the in vitro studies as well as the inhibitory effect of endoge nous opioid ligands in vivo (Seeger et aI., 1984) .
A comparison of Bmax estimates obtained from in vitro and in vivo experiments required conversion of the Bmax dimension. In Table 5 , the dimension of Bmax, i.e., fmol/mg of protein, was converted into pmol/g of brain tissue assuming 100 mg of protein (tissue membrane fraction)/g of brain tissue. Al though this conversion factor may not be precise, there was a correspondence between the in vivo and in vitro values when we combine Bmax values of mu and kappa receptor sites. Sadee et al . measured both in vivo and in vitro Bmax values with eH]di prenorphine and expressed them in the dimension of pmol/g of brain tissue (Perry et aI ., 1980; Sadee et aI ., 1982) . The in vivo Bmax values we determined with eH]CF are comparable to in vitro values (see Table 5 ).
The term Bmax is defined as the number of "available" recepors for CF binding and includes both unoccupied receptors and receptors that are reversibly interacting with endogenous substances J Cereb Blood Flow Metab. Vol. II . No . 2. 1991 within the time course of the experimental period. The agreement in Bm a x estimates between in vivo and in vitro suggest that CF competes with these endogenous substances and nearly estimates the to tal number of receptors in different brain regions. The extent of interaction of endogenous substances at the receptor sites would be observed as a change in KD estimate under these conditions, as men tioned above.
Potential applications
We have proposed alternatives to estimating K, and k2 from the time-activity data obtained follow ing i. v. bolus injection of lipophilic neuroreceptor ligands (Sawada et aI., 1990b) . Briefly, K, is calcu lated from a measurement of blood flow and an es timate of PS obtained from the octanol-water par tition coefficient of CF at pH 7.4 and its molecular weight (Fenstermacher, 1989; Sawada et aI., 1990a) ; k2 is obtained from the relationship de scribed by Eq. (1 1) . The values of K, and k2 are fixed and the CF time-activity data are fitted to three parameters (K�q, k�, and k�); the results are shown in Table 6 and can be compared to the four parameter (K� , K�q, k�, k�) fit of the same data shown in Table 2 . In addition, we have fixed the value of �q based on (a) the estimate obtained in cerebellum (see the legend to Table 5 ) and (b) the value obtained with the inactive enantiomer of CF [( + )-CF] in each brain structure (Kawai et aI., 1990b) ; using these values for K�q, the same data was fitted to two parameters (k� and k�) and the results are also presented in Table 6 .
The values of K, calculated from the extrapolated P S, and measured blood flow in different brain structures shown in Table 6 closely approximated the values of K, obtained by a four-parameter fit of the experimental data ( Table 2 ) and illustrates that transport across the BBB is highly dependent on blood flow when PS/K, > 2 (Tables 1, 2, and 6) . calculated from corrected tissue and blood radioactivity measurements ; Am/Cs is plotted against f�ekb(t'7)CB(T)dT/CB(t) (Patlak and Blasberg, 1985) . The ordinate has units of apparent distribution volume (ml/g) ; the abscissa has units of time (min) and has been described as "stretch time" or "normalized time. " For the inset to panel A, Am/CB is plotted against f�CB(T)dT/CB(t). Closed circles, cerebellum; open circles, frontal cortex; closed squares, thalamus. The curvilinear relationship for frontal cortex and thalamus indicates that [3H]CF uptake and binding to the opiate receptor is not irreversible. In panels A and B, the data are corrected to account for the rate of loss from the tissue (kb)' (C,D) The tissue activity ratio (Am/A ;") of parent [3H]CF was calculated from brain tissue data corrected for intravascular radioactivity and plotted against f&e -kb(t)Am(T)dT/A ;,, (t) where A;" is the activity (cpm/g) in a brain region devoid of opiate receptors (cerebellum) (Patlak and Blasberg, 1985) . The ordinate is a dimensionless distribution space ratio; the abscissa has units of time (min) as described above. The fitted value of the slope (K) and kb in panels A and B and the slope (K/v� + V�) and kb in panels C and D are based on a weighted least-squares regression and are given in Table 7 .
This similarity of values supports our assumption of passive diffusion of "free," unbound ligand across the BBB. The value of total distribution volume � for a given brain region was very similar for each of the analyses in Table 6 and was essentially the same as that shown in Table 2 . Corresponding values for the receptor binding potential k�/k� varied depending on the magnitude of nonspecific tissue binding K�q since the K�/k� ratio was fixed [Eq. (11) ] in all four analyses and k�/k� is related to � and �q by Eq. (A49). An accurate assessment of Keq can be essen tial for the accurate estimation of the desired pa-rameters (k� , k�) . This is particularly evident in structures with few or modest numbers of opiate receptors, such as parietal cortex, where rapid non specific binding accounts for a large fraction of total tissue radioactivity. In receptor-rich structures, such as thalamus and caudate nucleus, similar dif ferences in �q result in comparatively small differ ences in the estimates of k� , k�, and k�/k� (Table 6) .
The fo ur approaches we used in estimating k� and k� can be compared with respect to the residual sum of squares [Eq. (12) ] and the AIC [Eq. (14) ] . The SSs were only slightly greater in the two-and three parameter fits (Table 6) parameter fit ( Table 2 ). The AIC was lowest for parietal cortex using the three-parameter fit; for oc cipital cortex, caudate putamen, hippocampus, and medulla, the AIC was lowest for the two-parameter fit using cerebellum to estimate K e q; for frontal cor tex and thalamus, the AIC was lowest for the two parameter fit using K e q estimated with the inactive (+ )-CF enantiomer (Kawai et aI . , 1990b) . From a statistical point of view, the two-and three parameter fits of the experimental data presented in Table 6 appear to give more reliable estimates of the receptor binding parameters (k� , k� , and k�/k�) than simultaneous estimation of transport , rapid nonspe cific binding, and receptor-specific binding param eters (Table 2) .
This approach is substantially different from that proposed by Frost et al. (1989) . In their analysis, the K�/k� ratio was fixed on the basis of a four parameter (three-compartment model) fit of the [lIC]carfentanil time-activity data in occipital cor tex, a brain region assumed to be devoid of opiate receptors . The K�/k� ratios obtained in five subjects varied over a three-to fourfold range (0. 15-0. 65 and 0 . 24-0. 83 ml/g of brain with and without naloxone pretreatment, respectively). This large variation in the size of the "extracellular" (rapidly exchange able) compartment for [IIC]carfentanil between subjects is not physiologically tenable and reflects the inherent variation in the fit of the time-activity data from different subjects and does not account for differences in plasma protein binding of e IC] carfentanil in different subjects. By imposing a con straint on the fitting process based on Eq. (11), more consistent estimates of receptor binding pa- Table 3 ).
f k/k4 cortex, thalamus (see Table 2 ). Rothman and MacLean, (1988) . Frozen lysed P2 membranes were used. Binding study (50 mM Tris HCl, pH 7.4 in the presence of 100 mM NaCI) was carried out at O°C .
h fm ol/mg of protein was converted into 100 fmollg of brain.
� d Normal script: best fit of three parameters (K�q, k�, and k� ); bold script: best fit of two parameters (k�, k�), where K�q was determined from cerebellum data ( Table 2) ; underlined script: best fit of two parameters (k" k�), where Keq was determined from (+ )-CF data (Kawai et aI ., 1990b) .
e Free fraction in plasma [Eq. (3)]; free frac tion in blood (fb) was calculated by Eq. (6).
fEstimated from log PSe = 5.2 + log (partition coefficient · diffusion constant) (Sawada et aI ., 1990a ) . g Blood flow from Kawai et al . (l990a) (see Table 3 ). rameters are obtained that are based on the amount (concentration) of "free" ligand in tissue water (Blasberg et aI., 1989; Sawada et aI ., 1990a,b) .
To obtain estimates of Ko and Bmax , two or more studies must be performed over a fairly wide dose range that includes partial to near complete recep tor saturation. The data from these studies an� an alyzed simultaneously using a nonlinear pharmaco kinetic model to estimate kon ' kof[' and Bmax (Table  3 ). This analysis also requires knowledge of BBB transport (K I and k2) and nonspecific tissue binding (Keq). We assumed that K" k2 ' and Keq were con centration-independent parameters in our analysis and we used the values obtained from experiments using the lowest dose of CF (0. 5 nmol/rat). There fore , it may be advantageous to use the same strat egy as shown in Table 6 for the nonlinear estimation of kon' k O ff' and Bmax. For clinical studies using PET and i.v. injection of [,8F]CF, all six parameters could be obtained from a simultaneous fit of all of the data obtained from two or more studies over the dose range described above. Alternatively, K I and k2 could be calculated from measured blood flow, and the extrapolated PS I product as described above and by Sawada et ai . (1990b) . This approach reduces the number of parameter estimates by two.
CF has a modest receptor-off rate constant (k4 = 0.08-0. 16 min � I, Table 2 ; koff = 0. 1 6--0 . 22 min �', Table 3 ) and a modest brain loss constant (kb = 0.04-0 .08, Table 4 ) corresponding to a brain loss half-time of 9-18 min. These numbers indicate that tissue-blood equilibrium could be achieved in a rea sonable period of time and that equilibrium-type in vivo experiments using [,sF]CF could be performed to estimate Bmax, Ko, and Keq (Kawai et aI ., 1989) . Equilibrium experiments are an alternative ap proach to estimate receptor binding parameters and have the advantage of eliminating the influence of BBB transport and slow nonspecific binding on the analysis.
CONCLUSIONS
We developed and used a physiological-based model to analyze the CF data that accounts for the anatomical and fu nctional characteristics of brain microvessels. Four important observations result from this study.
(a) Similar tissue-binding parameters were ob tained with the physiological and classical pharma cokinetic models confirming the appropriate appli cation of classical compartmental analysis for the parameter estimations. In contrast, the use of the graphical method is not recommended because kb is not sufficiently small for CF.
J Cereb Blood Flow Metab . Vol. /I, No . 2, 1991 (b) Radiolabeled metabolites of eH]CF appear in blood but not in brain tissue; they are highly polar and can be determined by a simple ethyl acetate extraction at pH 9 .
(c) Estimates for rapid nonspecific tissue binding of eH]CF in vivo varied somewhat between differ ent brain structures (Keq = 3-9); Keq was small in comparison to estimates of specific receptor bind ing in central gray matter structures (BPr = 25-32), but represented one-fourth to one-half of the mea sured radioactivity in other brain structures (e.g., cortex and medulla, BPr = 9-15) .
(d) Estimates of kon ' k O ff' KD, and Bmax in differ ent brain structures could be obtained from in vivo experiments by i. v. bolus injection of different amounts of CF and corresponded well with values obtained in vitro.
The potential for clinical studies using [,sF]CF to yield quantitative estimates of k3 and k4 or kon' kof[, Ko, and Bmax from i.v. injection time-activity data by compartmental analysis does exist. Our ap proach was developed with the criteria that it must be applicable to clinical studies using PET. We sug gest a specific strategy that has general application and could be applied to other receptor-ligand sys tems in the human brain as well as other organs. binding sites in model A, min -I; Keq: equilibrium constant for all nonspecific binding sites in model A; IG: clearance constant of influx at BBB in model B, ml/min/g of tissue; k'2 : efflux rate constant at BBB in model B, min -1 ; k� : association rate term at receptor-binding sites in model B, min -1 ; k� : disso ciation rate term at receptor-binding sites in model B, min -I; �q: equilibrium constant for all nonspe cific binding sites in model B, min -I ; kon: bimolec ular association rate constant, min -I nM -I; ko rr : molecular dissociation rate constant, min -I; KD: dissociation constant, kof/kon, nM; Bm a x : number of receptors available fo r ligand binding, pmol/g of brain; CB, A r , Ap An' Afn, and AT: Laplace trans fo rm of CB , Af, Ap An' Afn, and AT' respectively; s: Laplace operator; V r : apparent volume of distribu tion of unbound, free drug, ml/g of tissue; Vd : phys ical volume of distribution, ml/g of tissue; VT : total volume of distribution in brain tissue, mllg of tissue; BP: binding potential ; K2 : kA I + KeqL min-I; K 3 : k /( 1 )
.
-I K C k C /( I K C )
• -I K C 3 + Keq , mill ; 2 : 2 + eq ' mill ; 3 : k�/( 1 + K�q), min -I; Am: total amount in the tissue (equivalent to AT), % dose/g of tissue ; K: overall steady-state uptake rate or clearance term (slope from graphical analysis), ml/min/g of tissue; kb : rate term for loss from the tissue, min I; k�: rate term for loss from the tissue using a second brain region as a reference, min -I; Ve : steady-state volume of the reversible compartments, mIlg of tissue ; V� : steady-state volume of the reversible compartments in the second region, mIlg of tissue; K+ : K/ V�, min -I; wb: water content of blood, ml water/ml of blood ; WT: water content of tissue, ml water/g of tissue; Aw: tissue to blood water partition coefficient (WT/Wb), ml blood/g of tissue.
APPENDIX II Physiological pharmacokinetic model for CF (model A, Fig . 1 ; Sawada et aI . , 1989) The mass continuity and transport equation for single capillary is given by
where C B is the sectional blood concentration [ = CB(x,t)] and is a function of both time (t) and dis tance (x) . If X is used as a dimensionless capillary length x/ l , Eqs. (Al) and (A2) may be written as follows:
a(Ar + A )
Letting Ar + An = Afn, the following equations are obtained after rearrangement:
The Laplace transforms of these equations are as follows (t � s, Afn � Afn, CB � CB) : In[H'(y)] was numerically solved (Hosono, 1983 ).
Nonlinear pharmacokinetic model for CF binding to opiate receptors (model B; Fig . 1) The differential equations are as follows:
assuming K�, k�, and �q are unchanged over the dose range of Af. Letting Af + An = A f n , the above equations may be rewritten as (A33)
where K o n = (kon)/( I + K�q) and K� = (k�)/( I + K�q) . Since Afn + Ar = AT' combining the latter equations yields 
The solution for these differential equations [Eqs.
(A35) and (A36)] with nonlinear conditions was ob tained numerically by· the Runge-Kutta-Merson method (Yamaoka and Nakagawa, 1983) .
Pharmacokinetic model for brain washout experiments
Simulation analysis of CF "washout" from brain after a bolus input was performed. The rate con-stants used in the simulations were obtained from the compartmental analyses of the i. v. injection ex periments (0.5 nmol/rat). The basic equations for simulation of brain washout are the same as those for the i.v. injection experiments [Eqs. (A22) and (A23) in the linear condition and Eqs. (A35) and (A36) in the nonlinear condition] . In order to simu late the brain washout profiles under pentobarbital anesthesia using transport and binding parameters in conscious rats, the same assumptions discussed in Sawada et al. (l990h) were used, namely all rate constants except K� and k� are unaffected by the anesthetic and that the K�/k� ratio and PSI are un affected by the anesthetic. Thus, 
for a single capillary system (Renkin, 1959; Crone, 1963) , where the superscript " a " refers to the value in anesthetized animals. Therefore,
k� a = k�(� a / K�) ) where the value of P in anesthetized animals was measured under the same conditions as the i.a. ex periments (Otsuki et aI., 1989) ; the value of F in the i. v. experiments was taken from Kawai et " al. (l990a) .
For the brain washout simulations, Cb is set equal to zero in Eqs. (An) and (A23) and the initial con ditions are
where M is the % dose/g of brain of micro spheres after intra-arterial administration. Simulation stud ies were carried out under these conditions using the parameters presented in Tables I and 2. APPENDIX III: BINDING POTENTIAL AND TOTAL VOLUME OF DISTRIBUTION
The binding potential (BP) (Mintun et aI., 1984 ) of a specific receptor-ligand interaction can be ex pressed as BP = k3/k4, where k3 is the rate term or coefficient for the association of ligand with the re ceptor in a particular brain region and k4 represents the apparent dissociation coefficient from the re ceptor. As can be seen from Eq. (A3 1), the relation ships for k3 and k4 are arbitrary for the nonlinear condition. However, we shall choose k3 to be the product of the bimolecular association rate constant (k o n) and the quantity of receptor sites available for binding (Bm a x), where some of the receptors may be reversibly occupied by endogenous ligands. Thus, k3 will be given by
where Vd is the physical volume of distribution of the ligand and is usually assumed to be unity in in vitro studies or equivalent to the tissue water space WT in in vivo studies; k4 will be given by
where C f is the concentration of unbound ligand, and Ko is the dissociation constant , equal to the ratio between kofr and kon. 
The apparent volume of distribution of unbound, free drug in the tissue at equilibrium (Vr) and the total volume of distribution (VT) are expressed as follows: 
where Keq and K�q is the equilibrium constant for rapidly reversible nonspecific binding.
